98%
921
2 minutes
20
Objective: This study explored the association between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).
Methods: A 9-year cohort study was performed among Chinese men who underwent their annual health checkups between 2009 and 2018. NAFLD was diagnosed based on abdominal ultrasound with exclusion of excess alcohol intake and other causes of liver disease. Logistic regression and Cox proportional regression analyses were applied to identify the risk of prevalent and incident T2DM.
Results: Of the 7,079 participants enrolled, 243 had T2DM at baseline and 630 developed T2DM during the 45,456 person-years follow-up. Both at the baseline and by the end of the follow-up, LMAC was associated with a decreased risk of prevalent T2DM in NAFLD-free participants but with a significantly increased risk in patients with NAFLD. LMAC was also associated with a decreased risk of incident T2DM in NAFLD-free participants. The adjusted hazard ratios (95% confidence interval) of incident T2DM were 0.224 (0.115-0.437) and 0.464 (0.303-0.710) for NAFLD-free light drinkers and NAFLD-free moderate drinkers, respectively. Nondrinking, light-drinking, and moderate-drinking patients with NAFLD all showed significantly increased risks of incident T2DM. Compared with NAFLD-free nondrinkers, the adjusted hazard ratios (95% confidence interval) of incident T2DM were 1.672 (1.336-2.092), 2.642 (1.958-3.565), and 2.687 (2.106-3.427) for nondrinking, light-drinking, and moderate-drinking patients with NAFLD, respectively.
Discussion: LMAC decreased the risks of prevalent and incident T2DM in NAFLD-free participants. LMAC, however, was associated with an increased risk of T2DM in patients with NAFLD (ClinicalTrials.gov number: NCT03847116).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14309/ajg.0000000000000607 | DOI Listing |
Minerva Cardiol Angiol
September 2025
Department of Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences, Nerul, Navi Mumbai, India.
Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.
View Article and Find Full Text PDFDiabetes Metab Syndr Obes
September 2025
Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, People's Republic of China.
Aim: This 10-year study aimed to evaluate how glycaemic control, diabetes duration and coronary stenosis severity affect mortality in patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) and to perform multifactorial risk analysis to find key modifiable factors for better risk stratification and secondary prevention.
Methods: This retrospective cohort study involved 150 patients with T2DM with chronic coronary syndrome who had coronary angiography at a single centre between 2011 and 2012. Demographic and biochemical data were collected.
Food Res Int
November 2025
School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan 610106, China. Electronic address:
Background: Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease characterized by insulin resistance and progressive decline in pancreatic beta cell function. It is a public health problem of great magnitude that has been increasing globally over the last 4 decades. The latest research has found that sugar-sweetened beverages (SSBs), as an important dietary risk factor, are closely related to the occurrence and development of T2DM.
View Article and Find Full Text PDFBMC Oral Health
September 2025
Department of Oral Medicine and Periodontology, Ain Shams University, Cairo, Egypt.
Background: Periodontitis, a chronic inflammatory disease of tooth-supporting tissues, shows significant associations with systemic conditions like type 2 diabetes mellitus (T2DM) and obesity. These metabolic disorders share chronic inflammatory pathways that may influence periodontal disease severity. This study investigated these relationships using advanced quantifiable metrics - periodontal epithelial surface area (PESA) and periodontal inflammatory surface area (PISA).
View Article and Find Full Text PDFDiabetes Metab Syndr Obes
August 2025
Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, People's Republic of China.
Background: Chinese herbal medicines (CHMs) are used for type 2 diabetes mellitus combined with stable angina pectoris (T2DM-SAP), but their long-term effects lack real-world evidence.
Objective: To evaluate the effects of additional CHMs on angina readmission rates compared to standard treatment alone in patients with T2DM-SAP.
Methods: This retrospective cohort study included 704 patients with T2DM-SAP.